Predict your next investment

Corporation
HEALTHCARE | Biotechnology
compasstherapeutics.com

See what CB Insights has to offer

Founded Year

2014

Stage

Reverse Merger | IPO

Total Raised

$132.58M

Market Cap

0.22B

Stock Price

3.55

About Compass Therapeutics

Compass Therapeutics, formerly Kairos Biologics Foundation, is comprehensively drugging the tumor-immune synapse with human antibodies against cell surfaces and soluble targets.

Compass Therapeutics Headquarter Location

245 First Street 3rd Floor

Cambridge, Massachusetts, 02142,

United States

617-500-8099

Latest Compass Therapeutics News

NEXGEL Announces Appointment of Miranda Toledano to Board of Directors

Sep 9, 2021

Ms. Toledano Brings Over Two Decades of Biopharmaceutical Wall Street Experience to NEXGEL News provided by Share this article Share this article LANGHORNE, Pa., Sept. 9, 2021 /PRNewswire/ --  NEXGEL, Inc.  ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that the Company has appointed Miranda Toledano to its Board of Directors. Ms. Toledano brings over 20 years of biotech, principal investment and capital markets experience to NEXGEL. Since its founding in 2018, Ms. Toledano served as Chief Operating Officer, Chief Financial Officer and Board member at TRIGR Therapeutics, a clinical stage immuno-oncology biotech company, recently acquired by Compass Therapeutics. "Miranda's strategic, operational leadership and transactional experience, shepherding biopharma companies from early stages of clinical development to commercialization, will be invaluable to NEXGEL as we continue to develop our Hydrogel technology across differentiated healthcare, consumer and novel clinical indications," said Adam Levy, NEXGEL CEO. "NEXGEL has quickly emerged as a leading provider of proprietary hydrogel technology with diverse ultra-gentle, high-water-content products that are now poised to disrupt both the medical and consumer markets," added Ms. Toledano. "The Company is currently reaching a critical value inflection point, and I look forward to working closely alongside NEXGEL's leadership team to support its novel programs and strategic development. "  Prior to joining TRIGR, Ms. Toledano served on the executive management team at Sorrento Therapeutics where she helped drive its immuno-oncology, CAR-T and pain franchises. Ms. Toledano previously served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she executed capital market transactions totaling over $4 billion in value. From 2004 to 2010, Miranda served as Vice President in the investment group at Royalty Pharma, where she worked on monetization transactions involving blockbuster auto-immune, oncology and infectious disease therapeutics. Earlier in her career, Ms. Toledano developed and served as Senior Manager in the life science corporate finance group at Ernst & Young Israel. Ms. Toledano is a member of the board of Compass Therapeutics, Entera Bio, Journey Medical and Lipomedix. Ms. Toledano holds a Master of Business Administration degree in Finance and Entrepreneurship from New York University's Stern School of Business, as well as a Bachelor of Arts degree in Economics from Tufts University. About NEXGEL, INC. NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation. Investor Contacts:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Compass Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Compass Therapeutics is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

13,989 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,592 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Compass Therapeutics Patents

Compass Therapeutics has filed 17 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/13/2019

6/29/2021

Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Experimental cancer drugs

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/13/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/29/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Experimental cancer drugs

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compass Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Compass Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.